이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

재발성 또는 진행성 교모세포종에서의 뇌실내 MT027 2상 임상시험 (GLIOMAX-101)

2026년 10월 8일 업데이트: T-MAXIMUM Pharmaceutical Inc

재발성 또는 진행성 교모세포종(WHO 4등급) 환자에서 뇌실내 투여되는 MT027의 안전성, 내약성, 효능, 약동학 및 약력학을 평가하기 위한 안전성 런인 단계가 포함된 2상 개방형 다기관 연구

This is a Phase II trial to evaluate the safety, tolerability, efficacy, and PK/ pharmacodynamic profiles of MT027 injected via ICV in participants with recurrent or progressive IDH-wildtype glioblastoma (WHO 2021 CNS Grade 4), who have previously received standard of care (SOC) therapy.

Each participant will undergo screening, treatment (receiving MT027 at a dose of 3×10^7 cells), safety follow-up, and long-term follow-up periods.

MT027 will be given via ICV injection on Day 1 & Day 15 of the first 28-day cycle. If the participant does not experience any unacceptable toxicities and disease progress in the first cycle, additional treatment may be continued bi-weekly in a 28-day cycle (Days 1 & Day 15 of the 28-day cycle) until intolerable toxicity, disease progression, withdrawal from the study, or death, whichever comes first. After the last dose, there will be a safety follow-up period lasting for 1 year and then a long-term follow-up up to 15 years.

연구 개요

상세 설명

This is a Phase II trial to evaluate the safety, tolerability, efficacy, and PK/ pharmacodynamic profiles of MT027 injected via ICV in participants with recurrent or progressive IDH-wildtype glioblastoma (WHO 2021 CNS Grade 4), who have previously received standard of care (SOC) therapy.

The study will begin with a safety run-in of 3 to 6 participants to evaluate the safety and tolerability of MT027 at a dose of 3×10^7 cells. Once the DLT assessment is complete, an additional 34 participants will be enrolled, bringing the total to 40, to evaluate the treatment's efficacy. Each participant will undergo screening, treatment, safety follow-up, and long-term follow-up periods. Any participant who has discontinued from study treatment other than disease progression will also continue to have tumor assessments until disease progression, initiation of subsequent anticancer therapies, withdrawal from the study, or death, whichever comes first. Upon completion of the safety follow-up, all patients, except those who died, withdrew consent, or were lost to follow-up, will enter to the long-term follow-up. It is regarded as the end of the study when the last participant has completed the 1-year long-term follow-up, or all participants have progressed, died, or lost to follow-up, whichever comes first. MT027 will be given via ICV injection on Day 1 & Day 15 of the first 28-day cycle, and the DLT observation period will be 28 days following the first dose of the first cycle (only for safety run-in group). After the DLT observation period, if the participant does not experience any unacceptable toxicities and disease progress, additional treatment may be continued bi-weekly in a 28-day cycle (Days 1 & Day 15 of the 28-day cycle) until intolerable toxicity, disease progression, withdrawal from the study, or death, whichever comes first. When confirming disease progression, the study treatment may still be continued if there's a potential for benefit, based on PI's discretion and the participant's willingness, particularly when there are no better treatment options available. Investigational product (IP) may be temporarily interrupted to allow safety management and will resume the study treatment dose after participant's adverse events are recovered to the Grade 1 level or baseline, per PI's discretion. After the last dose, there will be a safety follow-up period lasting for 1 year and then a long-term follow-up up to 15 years.

연구 유형

중재적

등록 (추정된)

40

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

      • Hualien City, 대만, 970473
        • Hualien Tzu Chi Hospital
        • 수석 연구원:
          • Shinn-Zong Lin, MD, PhD
        • 연락하다:
          • Shinn-Zong Lin, MD, PhD
          • 전화번호: 0000000000
      • Kaohsiung City, 대만, 833401
        • Chang Gung Memorial Hospital, Kaohsiung
        • 수석 연구원:
          • Fu-Yuan Shih, MD
        • 연락하다:
          • Fu-Yuan Shih, MD
          • 전화번호: 0000 000-000-0000
      • Taoyuan, 대만, 333423
        • Chang Gung Memorial Hospital, Linkou
        • 수석 연구원:
          • Kuo-Chen Wei, MD
        • 연락하다:
          • Kuo-Chen Wei, MD
          • 전화번호: 0000 0000000000
    • Maryland
      • Baltimore, Maryland, 미국, 21287
        • The Johns Hopkins Sidney Kimmel Cancer Center
        • 수석 연구원:
          • Solmaz Sahebjam, MD
        • 연락하다:
          • Solmaz Sahebjam, MD
          • 전화번호: 000-000-0000

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Patients must meet all the following inclusion criteria to be enrolled in the study (applied to all patients screened in safety run-in and dose expansion stage, unless specified):

    1. Written informed consent must be obtained prior to any procedures that are not considered SOC

    2. ≥ 18 years old and ≤ 70 years old on the day of signing informed consent, male or female

    3. According to the WHO Classification of Tumors of the CNS (2021), definitely diagnosed recurrent or progressive GBM, WHO Grade 4, which must meet all 3 of the following criteria:

      • According to the histological/molecular pathology, diagnosed with GBM WHO grade 4
      • According to the histopathology or radiological imaging, confirmed disease progression or recurrence
      • First recurrence after failure to the SOC therapy of newly diagnosed disease-Stupp regimen (which was surgery + standard RT + concurrent TMZ and adjuvant TMZ), or first recurrence after failure to the SOC therapy of newly diagnosed disease-Stupp regimen (which was surgery + standard RT + concurrent TMZ and adjuvant TMZ) and received Bevacizumab treatment
    4. Participants with either unresectable lesions, or with resectable lesions who have undergone prior surgical resection, or with resectable lesions and no planned reoperation within 3 months after enrollment based on Investigator's judgment

    5. Participants voluntarily provide the latest archival tumor or fresh biopsies FFPE samples (at least 8 consecutive non-stained sections) for B7H3 expression test by Immunohistochemistry (IHC), and the clinical pathology confirms positive B7H3 expression, defined as the proportion of 2+ and 3+ ≥ 20% (Reference refer to Appendix 13.1) or historical B7H3 positive expression within 12 months at the time of enrollment

    6. Karnofsky Performance Status (KPS) score ≥ 60

    7. Life expectancy of ≥ 12 weeks

    8. Adequate organ and marrow functions as defined below: (blood transfusion, blood component transfusion, or hematopoietic stimulating factors within 7 days prior to the first dose is not allowed)

      1. Hematological: Absolute neutrophil count (ANC) ≥ 1.5 × 109/L, platelets ≥ 100 × 109/L, and hemoglobin ≥ 90 g/L
      2. Hepatic: ALT and AST ≤ 3 × ULN, total bilirubin ≤ 1.5 × ULN
      3. Renal: Serum creatinine (Cr) ≤ 1.5 × ULN, or calculated Cr clearance ≥ 30.0 mL/min using Cockcroft-Gault formula
      4. Coagulation: International normalized ratio (INR) ≤ 1.5 and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN (participant is receiving anticoagulant therapy in which case the APTT and INR must be within the therapeutic range of intended use for the anticoagulant)
      5. Cardiac: Left ventricular ejection fraction (LVEF) > 50%
      6. Oxygen saturation ≥ 95% on room air
    9. Has adequate treatment washout period before IP treatment, defined as:

      Major surgery : ≥ 2 weeks§; Ommaya reservoir placement surgery was excluded Radiation therapy : ≥ 12 weeks (unless the progression is clearly outside the radiation field (e.g., beyond the high-dose region or 80% isodose line) or there is pathologic confirmation of disease progression) Chemotherapy :≥ 23 days for TMZ ; ≥ 6 weeks for Nitrosoureas or Mitomycin C (such as: Carmustine, Lomustine and so on) Biologic agents* (such as: PD1/PD-L1 antibodies) : ≥ 4 weeks Small molecule targeted drugs (TKIs such as Regorafenib and Anlotinib) : ≥ 3 weeks or 5 half-lives (including toxic metabolites), whichever is longer Other antitumor therapies :≥ 4 weeks

      §Any surgery incisions or wounds must be completely healed

      *Not including Bevacizumab

    10. Intracranial hemorrhage Grade ≤ 1 (per NCI-CTCAE v5.0), and toxicity from previous systemic treatment returns to ≤ Grade 1 or baseline before the first CAR-T dose (except alopecia)

    11. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) from the time of the pre-study visit, through the course of the study and for 120 days after the last dose of study medication

      • Female patients of childbearing potential should have a negative serum pregnancy within 72 hours prior to receiving the first dose of study medication
      • Patients of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year
      • Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately

Exclusion Criteria:

A patient meeting any of the following criteria is not eligible to participate in this study (applied to all patients screened in safety run-in and dose expansion stages, unless specified):

  1. Brainstem and thalamus recurrence, spinal cord dissemination or extracranial metastasis
  2. The largest diameter of a single tumor lesion > 5 cm, or the sum of the largest diameters of multiple lesions > 6 cm
  3. Symptoms and signs of chronic intracranial hypertension that are difficult to control with drugs (such as daily use of Mannitol > 500 mL or Dexamethasone > 15 mg or Methylprednisolone > 80 mg or other hormones at the same dose)
  4. Uncontrolled seizure or epilepsy aggravation requiring escalation of antiepileptic therapy over the last 4 weeks
  5. Participated in other therapeutic clinical trials within 4 weeks prior to screening
  6. Previously received other allogeneic tissue/solid organ transplantation OR other CAR-T cell therapy
  7. Previously received Carmustine wafer, oncolytic viruses or other intratumoral implants treatment (e.g., GLIADEL® Wafer)
  8. Prior history of severe allergy to any component or biological product of the investigational drug
  9. History of other malignancy within 5 years of screening with the following exceptions: a) adequately treated basal cell or squamous cell skin cancer, b) carcinoma in situ of the cervix, c) carcinoma in situ of the breast, d) local prostate cancer after radical resection and/ or definitive RT with stable prostate specific antigen (PSA) levels for 1 year
  10. Serious diseases such as active systemic infection, coagulation dysfunction, history of interstitial lung disease, radiation pneumonitis, or evidence of active pneumonia that is not considered appropriate by Investigator
  11. Clinically significant uncontrolled heart, lung, liver, renal and neuro insufficiency including Class III or above heart failure according to the New York Heart Association (NYHA) standard, Stage IV liver cirrhosis; chronic kidney disease (CKD) Stage III or above; Symptoms of severe respiratory failure involving other organs; Uncontrolled seizure activity and/or clinically evident progressive encephalopathy
  12. History or active autoimmune diseases. However, participants with type 1 diabetes mellitus, hypothyroidism requiring hormone replacement therapy, skin disease that do not require systemic treatment (vitiligo, psoriasis, or hair loss) may be allowed. For any uncertainty, it is recommended to consult the sponsor's medical monitor before signing the informed consent
  13. Received live vaccines within 2 weeks before the first IP treatment or plans to receive live vaccines during the study period
  14. Participants with a history of active pulmonary tuberculosis infection within 1 year, those participants with history more than 1 year prior to the first dose of IP may be considered suitable if there is no evidence of active pulmonary tuberculosis judged by Investigator
  15. Active hepatitis B virus infection or hepatitis C virus infection (defined as HCV-IgM antibody positive, if HCV-RNA is lower than the lower limit of detection, enrollment is allowed); Or human immunodeficiency virus (HIV) infection (defined as HIV antibody positive); Or positive in Treponema pallidum antibody test
  16. According to Investigator's judgment, the participant suffers from severe neurocognitive impairment
  17. Unable to safely undergo ICV injection related procedures
  18. Any disease that currently needs systemic steroid treatment
  19. Unavailable for the follow-up assessment or concern for participant's compliance with the protocol procedures
  20. Presence of any conditions that could, in the opinion of Investigator, compromise the participant's ability to participate in the study
  21. Subjects who are lactating -

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: MT027

Intracerebroventricular administration of MT027 (3×10^7 B7-H3 Targeted UCAR-T-cell)

MT027 will be injected intracerebroventricularly at a dose of 3×10^7 cells on Day 1 & Day 15 of each 28-day treatment cycle.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
12개월 전체 생존율(OS)
기간: 첫 투여부터 치료 후 12개월까지
첫 투여부터 치료 후 12개월까지
Incidence rate of Dose-limiting toxicity (DLT)
기간: From the first dose to 2 weeks after the second dose

Incidence rate of Dose-limiting toxicity (DLT) after treatment in the safety run-in stage

From the first dose to 2 weeks after the second dose

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 11월 30일

기본 완료 (추정된)

2028년 12월 13일

연구 완료 (추정된)

2029년 7월 31일

연구 등록 날짜

최초 제출

2026년 1월 27일

QC 기준을 충족하는 최초 제출

2026년 1월 27일

처음 게시됨 (실제)

2026년 2월 4일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 14일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 8일

마지막으로 확인됨

2026년 1월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다